Abstract: Methods of potentiating opioid-induced analgesia in a subject by administration of a phosphodiesterase (PDE) inhibitor or glial attenuator are described. In particular, the present invention is directed to methods of treating or preventing acute or subchronic pain by administration of a PDE inhibitor or glial attenuator, such as ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine), in combination with an opioid.

Abstract: A system for servicing a computer controlled machine comprising: a computer controlled machine including a device operable to perform a function, a controller controlling the operation of that device, and a data access port for transferring data and commands from the controller; and a service tool operably connected to the data access port, the service tool including a remote communications capability, a computer, and diagnostics and graphing software; and an expert observer system operably linked to the remote communications capability of the service tool and including historical machine data, machine sales information, software revisions for the controller, additional diagnostics software, and an expert observer capable of providing a mentor capability to the operator of a service tool.

Abstract: Methods for treating thrombotic disorders using sulfated polysaccharides such as fucoidans are disclosed.

Abstract: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Abstract: A system for servicing a computer controlled machine comprising: a computer controlled machine including a device operable to perform a function, a controller controlling the operation of that device, and a data access port for transferring data and commands from the controller; and a service tool operably connected to the data access port, the service tool including a remote communications capability, a computer, and diagnostics and graphing software; and an expert observer system operably linked to the remote communications capability of the service tool and including historical machine data, machine sales information, software revisions for the controller, additional diagnostics software, and an expert observer capable of providing a mentor capability to the operator of a service tool.

Abstract: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Abstract: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Abstract: This invention provides 5-HT.sub.1F agonists of Formula I; ##STR1## where A-B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.

Abstract: This invention provides 5-HT.sub.1F agonists of Formula I: ##STR1## where A-B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.

Abstract: This invention provides 5-HT.sub.1F agonists of Formula I: ##STR1## where A--B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.

Abstract: Methods for the treatment or prevention of migraines comprising administering to a mammal in need thereof a combination of a tachykinin receptor antagonist and a serotonin agonist are disclosed. The administration may be concurrent or sequential, with either of the two activities being administered first.

Abstract: The present invention provides a method for the treatment of migraine with compounds or compositions that are selective agonists of 5-HT.sub.1F receptors relative to other serotonin receptors that produce unwanted effects like vasoconstriction. The neurogenic meningeal extravasation that leads to the pain of migraine is inhibited.

Abstract: A method of improving the utility of electrochemical glucose sensors by decreasing either or both their settling time and their sensitivity to interfering compounds. In particular, the settling time of an electrochemical glucose sensor is improved by pretreating the operating electrode with a negative electric current at a constant current density. The sensor's sensitivity to intefering compounds is reduced by operating the sensor at a reduced voltage while the glucose concentration measurement is being made.

Abstract: Homogeneous membranes permeable to oxygen and glucose composed of hydrophilic polyurethanes that are capable of absorbing from 10 to 50% of their dry weight of water. Variations in the composition of the hydrophilic polyurethanes make possible the fabrication of membranes in which the ratios of the diffusion coefficients of oxygen to glucose can be varied over a wide range. These membranes can be used in the fabrication of an electrochemical glucose sensor intended for use in vivo as an aid in the treatment of diabetes mellitus.

Abstract: The present invention provides a method for immobilizing biomolecules on a conductive substrate to produce a biosensor.

Abstract: A biocompatible thin film electrical component is configured for use in a human body or other ionic liquid environment. A polyimide substrate is bonded to a glass carrier plate sized for handling by automatic equipment and a multiple-layer metal conductor is deposited on the substrate and patterned to define an electrical circuit or biosensor. The polyimide and the glass establish a bond therebetween that withstands handling yet is know using biocompatible releasing agents and techniques. The polyimide substrate and glass carrier plate preferably have similar thermal expansion properties to reduce the likelihood of fracture and delamination problems during release of the substrate from the carrier plate. An insulation layer covers the metal conductor and, in one embodiment, is made of polyimide having a cure temperature lower than the temperature at which interediffusion occurrs in the metal layers in the conductor.